Humira

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
Fierce Pharma
DTC ads
television ads
AbbVie
Humira
Gilead Sciences
Truvada
Allergan
Botox
Flag link:
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Yahoo/Reuters
ICER
drug pricing
AbbVie
Humira
Roche
Rituxan
Flag link:
Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
Fierce Pharma
Merck
Keytruda
Bristol-Myers Squibb
Pfizer
Eliquis
AbbVie
Humira
Flag link:
AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira
AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira
Motley Fool
AbbVie
Rinvoq
Humira
immunology
Flag link:
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024
Yahoo/Motley Fool
Merck
Keytruda
AbbVie
Humira
Pfizer
Bristol-Myers Squibb
Eliquis
JNJ
Imbruvica
Flag link:
5 Things You Need to Know From AbbVie's Q2 Earnings Results
5 Things You Need to Know From AbbVie's Q2 Earnings Results
Motley Fool
AbbVie
Humira
Venclexta
Imbruvica
hepatitis C
earnings
Flag link:
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
Fierce Pharma
AbbVie
Humira
biosimilars
Europe
psoriasis
rheumatoid arthritis
Skyrizi
Flag link:
FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch
FDA-approved Humira copycat from Merck, Samsung Bioepis will wait 4 years to launch
Endpoints
Merck
Samsung Bioepis
FDA
Humira
AbbVie
drug launches
biosimilars
Flag link:
Merck's biosimilar to AbbVie's Humira wins FDA approval
Merck's biosimilar to AbbVie's Humira wins FDA approval
Reuters
Merck
Hadlima
biosimilars
FDA
AbbVie
Humira
Flag link:
Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
Fierce Pharma
AbbVie
Humira
Gilead Sciences
Biktarvy
Truvada
Pfizer
Xeljanz
television ads
DTC ads
Flag link:
Why AbbVie's Stock Sank in the First Half of 2019
Why AbbVie's Stock Sank in the First Half of 2019
Motley Fool
AbbVie
Humira
biosimilars
M&A
Allergan
Flag link:
5 reasons AbbVie bought Allergan, and why they may not be enough
5 reasons AbbVie bought Allergan, and why they may not be enough
Biopharma Dive
AbbVie
Allergan
M&A
Humira
Botox
cash
diversification
Flag link:
AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants
AbbVie to acquire Allergan for $63 billion in megamerger of pharma giants
Stat
AbbVie
Allergan
M&A
Humira
Flag link:
Meet the Top Ten Drugs of 2024 (Maybe)
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
AbbVie
Humira
Merck
Keytruda
Eliquis
Bristol-Myers Squibb
Imbruvica
Opdivo
Revlimid
Celgene
Flag link:
Lilly’s Taltz scrapes win against Humira in psoriatic arthritis
Lilly’s Taltz scrapes win against Humira in psoriatic arthritis
Pharmaforum
Eli Lilly
Taltz
AbbVie
Humira
psoriatic arthritis
Flag link:
Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar
Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar
Fierce Pharma
Turkey
Iran
Humira
biosimilars
CinnaGen Pharmaceuticals
Flag link:
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Fierce Pharma
Eli Lilly
Incyte
olumiant
safety data
Humira
rheumatoid arthritis
Flag link:
AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst
AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst
Fierce Pharma
AbbVie
Humira
Skyrizi
drug launches
psoriasis
drug pricing
formulary
Flag link:
AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.
AbbVie stock up 1.3% after announcing resolution to litigation over Humira in the U.S.
Marketwatch
AbbVie
biosimilars
Humira
patents
Boehringer Ingelheim
Flag link:
Biosimilar competition to AbbVie’s Humira is eroding profits, but company says it has confidence in pipeline
Biosimilar competition to AbbVie’s Humira is eroding profits, but company says it has confidence in pipeline
Marketwatch
AbbVie
earnings
Humira
generics
Flag link:

Pages